CARE™ Primer on Biosimilars
The primer offers information on biologics and biosimilars, with a focus on the basic science, regulatory pathways, clinical data and implications, as well as legal perspectives.
- Biologic therapy has revolutionized the treatment of many rheumatological disorders, and drastically improved patient outcomes.
- Many biologic therapies used in rheumatology have gone, or are going off patent, and competitive biosimilars are being introduced.
- Biosimilars not only have implications for specialty fields, but also for the general delivery of health care in Canada.
What follows is a primer on biologics and biosimilars, updated to reflect a rheumatological perspective. This educational report was created in conjunction with CARE™ Faculty Member Dr. Philip Baer (Ontario Medical Association), and details the basic science, management and regulatory pathways, legal perspectives and recent clinical data on biosimilars. This report is also informed by various CARE™ faculties and recent biosimilar news.
This Rheumatology Biosimilars Primer is written as of July 2018 and is subject to update and refinement. It is based upon a multi-disciplinary CARE™ Primer on Biosimilars (produced Fall 2017). For more information on CARE™ visit CAREeducation.ca. To access the comprehensive primer visit: http://www.CAREeducation.ca/primer.
Philip A. Baer, MDCM, FRCPC, FACR
CARE™ Rheumatology Faculty
Ontario Medical Association
Scott Edwards, B.Sc., Pharm
Dr. H. Bliss Murphy Cancer Centre
Rob Laister, PhD
Princess Margaret Cancer Centre
Jason Thomas, RPh, B.Sc., Pharm
Juravinski Cancer Centre